E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Anti-Obesity Drugs"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 January 2013)

Special Issue Editor

Guest Editor
Dr. Raj Padwal

Faculty of Medicine & Dentistry, 2J2.00 WC Mackenzie Health Sciences Centre, University of Alberta, 8440 112 Street NW, Edmonton, AB T6G 2B7, USA
Interests: antiobesity drugs; bariatric surgery; bariatric care; hypertension; health outcomes research

Special Issue Information

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 800 CHF (Swiss Francs).

Keywords

  • antiobesity drug
  • sibutramine
  • orlistat
  • lipase inhibitor
  • cetilistat
  • contrave
  • empatic
  • buproprion
  • zonisamide
  • naltrexone
  • tesofensine
  • endocannabinoid receptor blocker
  • rimonabant
  • incretin
  • beta-3 blocker
  • adrenergic reuptake inhibitor
  • lorcaserin
  • serotonin agonist

Published Papers (3 papers)

View options order results:
result details:
Displaying articles 1-3
Export citation of selected articles as:

Review

Open AccessReview Obesity Drug Update: The Lost Decade?
Pharmaceuticals 2010, 3(12), 3494-3521; doi:10.3390/ph3123494
Received: 5 October 2010 / Revised: 17 November 2010 / Accepted: 23 November 2010 / Published: 24 November 2010
Cited by 9 | PDF Full-text (294 KB) | HTML Full-text | XML Full-text
Abstract
The growing worldwide obesity epidemic and obesity-related disorders present a huge unmet medical need for safe and effective anti-obesity medications. The discovery of leptin in 1994 was rapidly succeeded by a wave of related discoveries leading to the elaboration of a hypothalamic [...] Read more.
The growing worldwide obesity epidemic and obesity-related disorders present a huge unmet medical need for safe and effective anti-obesity medications. The discovery of leptin in 1994 was rapidly succeeded by a wave of related discoveries leading to the elaboration of a hypothalamic melanocortinergic neuronal circuit regulated by leptin and other central and peripheral signaling molecules to control energy homeostasis. The identification of specific neuronal subtypes along with their unique connections and expression products generated a rich target menu for anti-obesity drug discovery programs. Over the course of the last decade, several new chemical entities aimed at these targets have reached various stages or successfully completed the drug discovery/regulatory process only to be dropped or taken off the market. There are now in fact fewer options for anti-obesity drug therapies in late 2010 than were available in 2000. The challenge to discover safe and effective anti-obesity drugs is alive and well. Full article
(This article belongs to the Special Issue Anti-Obesity Drugs)
Open AccessReview Combinations of drugs in the Treatment of Obesity
Pharmaceuticals 2010, 3(8), 2398-2415; doi:10.3390/ph3082398
Received: 8 June 2010 / Revised: 9 July 2010 / Accepted: 15 July 2010 / Published: 27 July 2010
Cited by 8 | PDF Full-text (188 KB) | HTML Full-text | XML Full-text
Abstract
Obesity is a chronic disease associated with excess morbidity and mortality. Clinical treatment, however, currently offers disappointing results, with very high rates of weight loss failure or weight regain cycles, and only two drugs (orlistat and sibutramine) approved for long-term use. Drugs [...] Read more.
Obesity is a chronic disease associated with excess morbidity and mortality. Clinical treatment, however, currently offers disappointing results, with very high rates of weight loss failure or weight regain cycles, and only two drugs (orlistat and sibutramine) approved for long-term use. Drugs combinations can be an option for its treatment but, although widely used in clinical practice, very few data are available in literature for its validation. Our review focuses on the rationale for their use, with advantages and disadvantages; on combinations often used, with or without studies; and on new perspectives of combinations being studied mainly by the pharmaceutical industry. Full article
(This article belongs to the Special Issue Anti-Obesity Drugs)
Open AccessReview Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options
Pharmaceuticals 2010, 3(1), 125-145; doi:10.3390/ph3010125
Received: 8 November 2009 / Revised: 7 January 2010 / Accepted: 11 January 2010 / Published: 12 January 2010
Cited by 5 | PDF Full-text (261 KB) | HTML Full-text | XML Full-text
Abstract
Available anti-obesity pharmacotherapy options remain very limited and development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase energy [...] Read more.
Available anti-obesity pharmacotherapy options remain very limited and development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase energy expenditure. This review will focus on approved obesity medications, as well as potential new pharmacologic treatment options. Full article
(This article belongs to the Special Issue Anti-Obesity Drugs)

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Manuscript ID: Pharmaceuticals-antiobsi-20090905-Tzotzas-gr
Type of Paper: Review
Title: The Effect of Incretin-Based Pharmacotherapy on Body Weight
Author: Spiridon Karras, Gerasimos Krassas and Themistoklis Tzotzas; E-Mail: tzotzas@otenet.gr
Abstract: Incretin–based pharmacotherapy, represented by Glucagon-Like Peptide-1(GLP-1) mimetics and DPP-4 inhibitors, offers a new therapeutic approach in Type 2 Diabetes Mellitus (T2DM).These glucosemodulatory agents enhance insulin secretion, lower fasting and postprandial glucose, suppress glucagon secretion and may have pleiotropic metabolic effects; additionally, they participate in the reduction of gastric emptying. Clinical studies demonstrated that GLP-1 mimetics increase postprandial satiety leading to reduced food intake and weight loss. These drugs induce food intake suppression mediated by distinct, but overlapping, peripheral and central pathways. On the contrary, DPP-4 inhibitors have a weight neutral effect. This review summarizes the current knowledge on the effect of incretin–based pharmacotherapy on body weight in T2DM and proposes an integrated model of the incretins on food intake .

Journal Contact

MDPI AG
Pharmaceuticals Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
pharmaceuticals@mdpi.com
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Pharmaceuticals
Back to Top